Literature DB >> 8458477

Acute urinary retention after gonadotropin-releasing hormone agonist treatment for leiomyomata uteri.

A J Friedman1.   

Abstract

A case of rapid uterine enlargement and subsequent urinary retention occurring 7 days after GnRH-a administration in a 53-year-old premenopausal woman with myomas is presented. Rapid uterine enlargement was presumed to be caused by hyperestrogenism shortly after GnRH-a administration. The patient was treated with an indwelling Foley catheter for 2 weeks until the uterus decreased to near baseline dimensions. The patient's uterus continued to decrease in size during the 12 weeks she received GnRH-a, and she underwent an uneventful total abdominal hysterectomy and bilateral salpingectomy/oophorectomy after donating 2 units of autologous blood. This case illustrates that adverse effects from GnRH-a treatment may be caused by the transient increase in ovarian steroid secretion shortly after drug administration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8458477     DOI: 10.1016/s0015-0282(16)55821-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

Review 1.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Urinary retention and uterine leiomyomas: a case series and systematic review of the literature.

Authors:  Clara Q Wu; Guylaine Lefebvre; Helena Frecker; Heinrich Husslein
Journal:  Int Urogynecol J       Date:  2015-03-10       Impact factor: 2.894

3.  Fibroid-induced acute urinary retention: treatment by uterine artery embolization.

Authors:  Elizabeth Kagan Arleo; Michael G Tal
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-02

Review 4.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.